The End of the Beginning: The Evolving Landscape of Alzheimer’s Disease Pharmacotherapy
  • Ipsos
  • Insights Hub
  • The End of the Beginning: The Evolving Landscape of Alzheimer’s Disease Pharmacotherapy
The End of the Beginning: The Evolving Landscape of Alzheimer’s Disease Pharmacotherapy

The End of the Beginning: The Evolving Landscape of Alzheimer’s Disease Pharmacotherapy

Read more about the recent breakthroughs, ongoing challenges, and future directions of Alzheimer’s disease pharmacotherapy.

The Alzheimer’s disease market is forecast to grow from approximately $0.2 billion in 2023 to $7.8 billion in 2030. After decades of setbacks, this field appears to be at a pivotal point, with multiple novel therapies set to reshape the treatment landscape in the coming years. However, past challenges and regulatory hurdles have highlighted the need for more comprehensive solutions and ongoing innovation.

The field is moving towards earlier diagnosis and intervention, while also exploring promising research pathways beyond anti-amyloid and tau-targeting approaches. Continued investment across a range of modalities will be critical, as will the incorporation of novel biomarkers and imaging tools to enable precision medicine.

Download our latest whitepaper exploring the past, present, and future of Alzheimer’s disease pharmacotherapy.

The author(s)

  • Joel Sandler, PhD
    Associate Partner, Healthcare Advisory

Related news

  • [WEBINAR] KEYS: The Year in Review
    Consumers Webinar

    [WEBINAR] KEYS: The Year in Review

    Join Ipsos for its complimentary KEYS webinar series dedicated to helping brands and organizations better understand the dynamics of today as they prepare for tomorrow.
  • Automotive Disruption and Trends Webinar
    Consumers Events replay

    Automotive Disruption and Trends Webinar

    Revisit Ipsos and SAA for a discussion on the future of mobility based on insights from the 2025 Ipsos Navigator Study.
  • Obesity Week
    Public Health Event

    Obesity Week

    This is a conference that encompasses the full spectrum of obesity science: from basic science research, to translational research and clinical application, to public policy; from diet, exercise, lifestyle, and psychology to medical and surgical interventions; from pediatric to geriatric to underserved populations.